AR128077A1 - Método para una rápida producción de células t modificadas genéticamente - Google Patents
Método para una rápida producción de células t modificadas genéticamenteInfo
- Publication number
- AR128077A1 AR128077A1 ARP220103561A ARP220103561A AR128077A1 AR 128077 A1 AR128077 A1 AR 128077A1 AR P220103561 A ARP220103561 A AR P220103561A AR P220103561 A ARP220103561 A AR P220103561A AR 128077 A1 AR128077 A1 AR 128077A1
- Authority
- AR
- Argentina
- Prior art keywords
- cells
- genetically modified
- population
- rapid production
- mixed mononuclear
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 210000005087 mononuclear cell Anatomy 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000012642 immune effector Substances 0.000 abstract 2
- 229940121354 immunomodulator Drugs 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2318—Interleukin-18 (IL-18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163292843P | 2021-12-22 | 2021-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128077A1 true AR128077A1 (es) | 2024-03-20 |
Family
ID=86903666
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103561A AR128077A1 (es) | 2021-12-22 | 2022-12-22 | Método para una rápida producción de células t modificadas genéticamente |
| ARP230102033A AR130098A1 (es) | 2021-12-22 | 2023-08-02 | Producción rápida de células t |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102033A AR130098A1 (es) | 2021-12-22 | 2023-08-02 | Producción rápida de células t |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250027042A1 (enExample) |
| EP (2) | EP4453188A4 (enExample) |
| JP (2) | JP2024546145A (enExample) |
| KR (1) | KR20240123837A (enExample) |
| CN (1) | CN119698465A (enExample) |
| AR (2) | AR128077A1 (enExample) |
| AU (1) | AU2022422123A1 (enExample) |
| CA (1) | CA3239503A1 (enExample) |
| CL (1) | CL2024001919A1 (enExample) |
| CO (1) | CO2024008914A2 (enExample) |
| IL (1) | IL313516A (enExample) |
| MX (1) | MX2024007669A (enExample) |
| UY (1) | UY40089A (enExample) |
| WO (2) | WO2023122277A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119698465A (zh) * | 2021-12-22 | 2025-03-25 | 克尔人工智能公司 | 快速t细胞制造 |
| KR20260096851A (ko) | 2023-10-18 | 2026-06-24 | 티큐 테라퓨틱스 게엠베하 | 세포 치료제 제조 방법 및 관련 키트와 장치 |
| EP4725578A1 (en) | 2024-10-08 | 2026-04-15 | TQ Therapeutics GmbH | Column designs for affinity chromatography |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5244806A (en) * | 1985-08-26 | 1993-09-14 | Eli Lilly And Company | DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells |
| CN108884460B (zh) * | 2016-03-19 | 2023-04-28 | 埃克苏马生物技术公司 | 淋巴细胞转导及其扩增调节的方法与组合物 |
| GB201622044D0 (en) * | 2016-12-22 | 2017-02-08 | Ucl Business Plc | T cell-targeted T cells |
| CN113840911A (zh) * | 2018-09-02 | 2021-12-24 | 埃克苏马生物技术公司 | 用于在血液中或在富集pbmc中基因修饰淋巴细胞的方法和组合物 |
| CN119698465A (zh) * | 2021-12-22 | 2025-03-25 | 克尔人工智能公司 | 快速t细胞制造 |
-
2022
- 2022-12-22 CN CN202280085189.1A patent/CN119698465A/zh active Pending
- 2022-12-22 MX MX2024007669A patent/MX2024007669A/es unknown
- 2022-12-22 AR ARP220103561A patent/AR128077A1/es unknown
- 2022-12-22 IL IL313516A patent/IL313516A/en unknown
- 2022-12-22 WO PCT/US2022/053815 patent/WO2023122277A2/en not_active Ceased
- 2022-12-22 UY UY0001040089A patent/UY40089A/es unknown
- 2022-12-22 JP JP2024535789A patent/JP2024546145A/ja active Pending
- 2022-12-22 CA CA3239503A patent/CA3239503A1/en active Pending
- 2022-12-22 US US18/714,302 patent/US20250027042A1/en active Pending
- 2022-12-22 EP EP22912490.4A patent/EP4453188A4/en active Pending
- 2022-12-22 AU AU2022422123A patent/AU2022422123A1/en active Pending
- 2022-12-22 KR KR1020247024364A patent/KR20240123837A/ko active Pending
-
2023
- 2023-06-19 WO PCT/US2023/025663 patent/WO2024136920A1/en not_active Ceased
- 2023-06-19 JP JP2025536953A patent/JP2026501322A/ja active Pending
- 2023-06-19 EP EP23908030.2A patent/EP4638711A1/en active Pending
- 2023-08-02 AR ARP230102033A patent/AR130098A1/es unknown
-
2024
- 2024-06-21 CL CL2024001919A patent/CL2024001919A1/es unknown
- 2024-07-04 CO CONC2024/0008914A patent/CO2024008914A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024136920A4 (en) | 2025-06-12 |
| CA3239503A1 (en) | 2023-06-29 |
| WO2023122277A2 (en) | 2023-06-29 |
| AR130098A1 (es) | 2024-11-06 |
| CO2024008914A2 (es) | 2024-08-08 |
| AU2022422123A1 (en) | 2024-07-11 |
| CL2024001919A1 (es) | 2024-12-06 |
| IL313516A (en) | 2024-08-01 |
| EP4453188A4 (en) | 2025-12-03 |
| CN119698465A (zh) | 2025-03-25 |
| WO2023122277A3 (en) | 2023-08-24 |
| WO2024136920A1 (en) | 2024-06-27 |
| MX2024007669A (es) | 2024-07-09 |
| EP4453188A2 (en) | 2024-10-30 |
| UY40089A (es) | 2023-07-14 |
| US20250027042A1 (en) | 2025-01-23 |
| JP2024546145A (ja) | 2024-12-17 |
| EP4638711A1 (en) | 2025-10-29 |
| KR20240123837A (ko) | 2024-08-14 |
| JP2026501322A (ja) | 2026-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR130098A1 (es) | Producción rápida de células t | |
| MX2020013236A (es) | Acido ribonucleico (arn) circular para traduccion en celulas eucariotas. | |
| CY1123254T1 (el) | Μεθοδοι για μεταγωγη και επεξεργασια κυτταρων | |
| MX382541B (es) | Métodos para aislar, cultivar y diseñar genéticamente poblaciones de células inmunes para terapia adoptiva. | |
| ES2543629T3 (es) | Células productoras de polipéptidos | |
| CO6290704A2 (es) | Virus de la estomatitis vesicular (vsv) atenuado y geneticamente modificado y composiciones inmunogenicas que lo contienen. | |
| MX2022005389A (es) | Terapia de celulas t con receptor de antigeno quimerico. | |
| BR112019008560A2 (pt) | célula artificial que apresenta antígeno, método para expandir linfócitos infiltrantes de tumor, para tratar um câncer com uma população de linfócitos infiltrantes de tumor e para avaliar a potência de linfócitos infiltrantes de tumor, kit, população de linfócitos infiltrantes de tumor, e, combinação | |
| AR078544A1 (es) | Procedimiento de cultivo de celulas de mamiferos para la produccion de proteinas | |
| AR077369A1 (es) | Metodopara producir eritrocitos sin celulas alimentadoras | |
| MX2016010171A (es) | Metodos para producir celulas t autologas utiles para tratar desordenes de celulas b y otros tipos de cancer, y composiciones de las mismas. | |
| MX2019003719A (es) | Sistema y metodo para gestionar la salida de potencia de una celda fotovoltaica. | |
| BR112021019349A2 (pt) | Células-tronco preparadas altamente funcionais | |
| MX2022002763A (es) | Linfocitos t modificados por ingenieria genetica que tienen persistencia mejorada en cultivo. | |
| MX2018006373A (es) | Produccion de virus en cultivos celulares. | |
| HRP20211803T1 (hr) | Genska terapija | |
| NO20081732L (no) | Cellekjerneoverforing | |
| BR112018015791A2 (pt) | amplificador de potência em matriz | |
| BR112022003852A2 (pt) | Métodos de preparação de células t para terapia de células t | |
| MX2024001208A (es) | Celulas primarias geneticamente modificadas para terapia celular alogenica. | |
| MX2024006051A (es) | Nuevos andamios de proteinas tale con relaciones de actividad en objetivo/fuera de objetivo mejoradas. | |
| MX2018003354A (es) | Seleccion de celulas pluripotentes para producir ratones hembra xy fertiles. | |
| CA2796599A1 (en) | Method for producing induced pluripotent stem cells | |
| CL2008003821A1 (es) | Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado | |
| CO2023018654A2 (es) | Método para producir linfocitos citolíticos naturales a partir de células madre pluripotentes |